Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Down 0.5 %

PULM opened at $6.26 on Friday. The company has a market cap of $22.86 million, a price-to-earnings ratio of -2.37 and a beta of 1.52. The company’s 50 day moving average is $5.36 and its 200 day moving average is $3.24. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.